Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473681 | 0.89 | SMN1; SMN2 (0.64) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL9373416 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL4996799 | 0.84 | LMNA (0.49) | ALDH1A1LMNAALOX5HPGD | |
| SCHEMBL255679 | 0.79 | CYP1A2 (0.71) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL619526 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL255663 | 0.79 | CYP1A2 (0.71) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL2007222 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL255664 | 0.79 | CYP1A2 (0.71) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL3985690 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL8309864 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | RIB-X PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | PCNA, PGC, MKI67 | SMN1; SMN2 3267/4885POLB 173/4885ALDH1A1 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.